High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood

Gustave Roussy

Status and phase: Unknown; Phase 2

Conditions: Brain Tumors; Neuroectodermal Tumors, Primitive; Medulloblastoma

Treatments: Drug: Etoposide, carboplatin, melphalan, cisplatin, thiotepa

Study type: Interventional

Funder types: Other

Identifiers

NCT00180791

PNET HR

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy of the combination of surgery, conventional chemotherapy, sequential high-dose chemotherapy with peripheral blood stem cell transplantation and reduced dose radiation therapy in high-risk PNET brain tumors.

Enrollment: 71 estimated patients

Sex: All

Ages: Under 10 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Medulloblastoma in patients less than 5 years of age
• Brain PNET in patients less than 10 years of age
• Histologically documented diagnosis
• Body weight of > 8 kg

Exclusion criteria

• Parents' refusal

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)